Jump to main content
Research Type: Articles
-
Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
Read More
-
Time to Throw in the Towel on Biosimilars
Read More
-
Mortgaging New Treatments Kicks the Can on High Drug Prices
Read More
-
Analysis of Medicare Part D Plans Shows $9B Upcharge
Read More
-
Fact Checking the NYT Fact Check on the Trump Proposal
Read More
-
DPL Policy Tracker Collects Drug Pricing Legislation and Proposals
Read More
-
A $475,000 price tag for a new cancer drug: crazy or meh?
Read More
-
Baseball Illuminates the Problem with U.S. Drug Pricing
Read More
-
DPL and Collaborators to Publish Drug Pricing Primer Series
Read More
-
Is Outcomes-Based Contracting Worth It?
Read More